Patients
allergy, CIPN, pain
ADVERSE EVENT, ALLERGY, COMPLICATIONS
Key eligibility criteria included age ≥ 20 years, a diagnosis of CIPN grade ≥ 2 according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, and a pain numerical rating scale (NRS) score ≥ 4; patients had colorectal, gastric, non-small-cell lung, or breast cancer and were undergoing chemotherapy with a regimen including oxaliplatin or taxane. Patients with pain due to causes other than CIPN (as carefully judged by the attending physician), with allergy to mirogabalin, and with major organ complications were excluded. Full eligibility criteria are provided in the Of the patients enrolled in the registrational study or from outside the registrational study, those who provided written informed consent to participate in and met the eligibility criteria for this interventional study were enrolled. Most patients were enrolled from the MiroCIP registrational study, but 16 patients were enrolled from outside the MiroCIP registrational study to ensure the pre-specified target sample size.